FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Adverse Event topics
Adverse Event
Clindamycin
User Interface
Pirfenidone
Adverse Effect
Doxycycline
Glucocorticoid
Psychiatric
Amelioration
Neurological
Prophylaxis
Gastric Balloon
Food And Drug Administration
Computer Readable
Electronic Health Record

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Adverse Event patents



      
           
This page is updated frequently with new Adverse Event-related patent applications. Subscribe to the Adverse Event RSS feed to automatically get the update: related Adverse RSS feeds. RSS updates for this page: Adverse Event RSS RSS


Date/App# patent app List of recent Adverse Event-related patents
11/06/14
20140328833
 Methods for treating cancer using anti-pd-1 antibodies patent thumbnailMethods for treating cancer using anti-pd-1 antibodies
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/16/14
20140309198
 Method of treating acne patent thumbnailMethod of treating acne
An improved method for treating acne is described. The method involves 16-week, once daily, oral administration of about 40 mg doxycycline in a pharmaceutical composition containing about 30 mg doxycycline in an immediate release portion and about 10 mg doxycycline in a delayed release portion.
10/02/14
20140294852
 Monoclonal antibodies to programmed death 1 (pd-1) patent thumbnailMonoclonal antibodies to programmed death 1 (pd-1)
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
09/04/14
20140250224
 Adverse event data capture and alert systems and methods patent thumbnailAdverse event data capture and alert systems and methods
Electronic capture of adverse event information includes selective input of adverse event information into a machine in response to prompt provided to the user based on a site visit. Such adverse event information is forwardable to a location over a communication link.
08/28/14
20140243690
 Systems and methods for the adaptive diagnosis of heart failure patent thumbnailSystems and methods for the adaptive diagnosis of heart failure
A cardiac implant includes a classifier configured analyze the data for comparison to thresholds prioritized according to a boolean decision tree. The implant can generate an indicator of alert status (i.e., alert or no alert).
08/28/14
20140243344
 Combination als therapy patent thumbnailCombination als therapy
Provided is a method for treating als in a subject, comprising administering to the subject a therapeutically effective amount of riluzole and a therapeutically effective amount of ck-2017357. Also provided are methods of reducing the variability of riluzole exposure (e.g., cmax and/or auc24h) in a subject, methods of reducing the variability of riluzole exposure (e.g., cmax and/or auc24h) between two or more subjects, methods of decreasing the total daily dose of riluzole in a subject, methods of increasing the half-life of riluzole in a subject, methods for decreasing the frequency of riluzole dosing in the subject, and methods for reducing the incidence and/or severity of adverse events in a subject treated with riluzole..
08/14/14
20140228316
 Pps for the prevention of potential adverse effects caused by cd3 specific binding domains patent thumbnailPps for the prevention of potential adverse effects caused by cd3 specific binding domains
The present invention relates to a pps for use in the amelioration, treatment or prophylaxis of neurological adverse events caused by a cd3 binding domain. Kits comprising a pps, a cd3 binding domain and instructions for use which indicate that the pps is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said cd3 binding domain, are also disclosed..
08/14/14
20140227272
 Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains patent thumbnailAnti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains
The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian t-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells are also contemplated..
08/07/14
20140221434
 Altering pharmacokinetics of pirfenidone therapy patent thumbnailAltering pharmacokinetics of pirfenidone therapy
The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) therapy.. .
07/31/14
20140212422
 Methods for treating cancer using anti-pd-1 antibodies in combination with anti-ctla-4 antibodies patent thumbnailMethods for treating cancer using anti-pd-1 antibodies in combination with anti-ctla-4 antibodies
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
07/17/14
20140200922
System and method for patient care
Embodiments of the present invention may integrate and analyze the output from various medical devices and clinical information systems in order to assist the clinical staff in making the more informed clinical decisions, output intelligent alarms, predict and prevent adverse events, and in some circumstances enable automated patient care.. .
07/17/14
20140200914
Data collection
Computer implemented methods of collecting data relating to an adverse event relating to use of a substance is provided. One method comprises detecting a user input relating to an identity of the substance or to an identity of the adverse event; determining the identity of the substance or of the adverse event based on the user input; and selectively displaying to the user at least one further request for information, wherein the content of the request displayed to the user is dependent on the identity of the substance or of the adverse event.
07/10/14
20140193498
Compositions and methods for treating metabolic disorders
Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release.. .
07/03/14
20140187519
Biomarkers for predicting major adverse events
Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin c..
06/12/14
20140164265
Clinical trial adverse event reporting system
A system is provided that sends data to a safety compliance management system in response to an adverse event. The system receives a first event in response to a first interaction by a user, where the first event indicates that the adverse event is to be reported to the safety compliance management system.
06/12/14
20140164015
Clinical trial adverse event data change reporting system
A system is provided that sends data changes to a safety compliance management system. The system defines at least one data field as a significant data field.
06/12/14
20140161899
Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins
The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine proteaseper ml of the plasma fraction.. .
05/01/14
20140122121
Interoperable case series system
A system is provided that integrates a case series repository with one or more software applications. The system receives a case series, where the case series includes one or more adverse event cases, and the system further receives a case revision, where the case revision includes case revision information.
05/01/14
20140121659
Electrogram-based ablation control
Methods, devices, and systems for predicting, diagnosing, and preventing adverse events during an ablation procedure are described. A method for providing ablation energy includes receiving a first signal based on biological activity of a tissue of a patient.
04/24/14
20140112970
Sustained release delivery of active agents to treat glaucoma and ocular hypertension
The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s)..
04/17/14
20140107404
Systems, methods and devices for performing gynecological procedures
Systems, methods, apparatus and devices for performing improved gynecologic and urologic procedures are disclosed. The system and devices provide simplified use and reduced risk of adverse events.
04/17/14
20140105959
Method and device for reducing dermal filler adverse events
Methods and devices of aesthetically enhancing and improving appearance of aging skin are provided. Methods may include the steps of treating a skin site selected for dermal filler administration with a mechanism effective to enhance drug delivery across the skin, applying to the treated site, a device, compound or formulation including an active agent effective to reduce visible bruising due to administration of a dermal filler into the site, and administering a dermal filler into the skin site thereby reduce the appearance of wrinkles or folds in the skin site without causing significant bruising.
04/10/14
20140101232
Electronic adverse event reporting system
An adverse event reporting system and related methods are provided. Aspects relate to a associating a unique identifier of a device with resolution information configured to be automatically transmitted in response to an adverse event with the device.
04/03/14
20140095201
Leveraging public health data for prediction and prevention of adverse events
An adverse event may be prevented by predicting the probability of a given patient to have or undergo the adverse event. The ability to predict the probability of the adverse event may be enhanced when a model is derived from public health data to categorize and propose values for medical record fields.
03/06/14
20140067407
Personal user dashboard
Systems, methods, and other embodiments associated with a personal user dashboard are described. In one embodiment, a method includes extracting, from one or more databases, case processing information about adverse events processed by a group of users.
03/06/14
20140066968
Intragastric balloon shell materials and construction
An intragastric balloon with a 12-month lifespan. The intragastric balloon has a shell made of a material with as good as or better than initial mechanical properties of previous materials; i.e.
01/30/14
20140031711
Correlating brain signal to intentional and unintentional changes in brain state
Methods of analysis to extract and assess brain data collected from subject animals, including humans, to detect intentional and unintentional brain activity and other unexpected signals are disclosed. These signals are correlated to higher cognitive brain functions or unintended, potentially adverse events, such as a stroke or seizure, and to translation of those signals into defined trigger events or tasks..
01/16/14
20140018890
Medical probes for the treatment of blood vessels
Devices and methods for thermally-mediated treatment of blood vessels to elicit an immune response to cause rapid endothelial growth over at least portions of an implant or stent to prevent adverse events such as restenosis. Devices and methods for thermally-mediated treatment to inhibit contraction of vessels to.
01/09/14
20140010822
Antibody therapeutics with local activity in the digestive tract
This invention provides methods and compositions of antibody therapeutics that are therapeutically effective in the digestive tract or below the mucosal barrier of the digestive tract but do not deliver levels of antibody to the systemic circulation that have been shown to be necessary for clinical benefit following systemic administration of antibody. This invention further describes therapeutic compositions of antibody therapeutics that are therapeutically effective in the digestive tract or below the mucosal barrier of the digestive tract but do not deliver levels of antibody to the systemic circulation that have been associated with adverse events and systemic immunosuppression following systemic administration of antibody..
12/19/13
20130337016
Method for treatment of acne using pharmaceutical compositions of clindamycin and adapalene
The present invention relates to a method for treating, reducing or preventing acne. In particular, the present invention relates to methods for reducing the total number, incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions.
11/28/13
20130317050
Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
Presented herein are methods for treatment or prevention of opioid induced constipation by administration of oral compositions of methylnaltrexone. The methods are based, at least in part, on the identification of subjects that are particularly susceptible to such treatment and optimal dosages of such oral compositions to treat or prevent opioid induced constipation and, further, to minimize the occurrence of adverse events associated with such treatment..
11/21/13
20130311466
Computer algorithms and methods for product safety
The invention comprises systems, methods and a computerized, data management device for creating and using data relating to a medical or non-medical product or device to enhance the safety of the product or device. A vast amount of data regarding adverse events associated with a particular product or device is analyzed to identify new essential adverse events associated with the product or device.
11/07/13
20130295086
Antibodies selective for cells presenting egfr at high density
Herein described are antibodies to epidermal growth factor receptor (egfr) having an egfr binding affinity that is sufficient to kill disease cells presenting egfr at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells..
10/31/13
20130287774
Prevention of adverse effects caused by cd3 specific binding domains
The present invention relates to a glucocorticoid (gc) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a cd3 binding domain. Kits comprising a gc, a cd3 binding domain and instructions for use which indicate that the gc is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said cd3 binding domain, are also disclosed..
10/10/13
20130268297
Direct reporting of adverse events
Systems, methods, and computer readable media are described for communicating an adverse event report directly to an end-user receiving party and tracking one or more adverse event reports. An adverse event may be detected manually or automatically by a system and an electronic adverse event reporting form presented to a user with one or more data fields pre-populated with data from a patient's electronic health record (ehr).
10/10/13
20130267983
Intragastric balloon shell materials and construction
An intragastric balloon with a 12-month lifespan. The intragastric balloon has a shell made of a material with as good as or better than initial mechanical properties of previous materials; i.e.
10/10/13
20130266654
Method for treatment of acne using pharmaceutical compositions of clindamycin
The present invention relates to a method for treating, reducing or preventing acne. In particular, the present invention relates to methods for reducing the total number, incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions.
10/10/13
20130263905
Adverse event-resilient network system
An adverse event-resilient network system consisting of autonomously powered and mobile nodes in communication with each other either through radio, light or other electromagnetic signals or through a physical connection such as through wiring, cables or other physical connected methods capable of carrying information and communication signals. The nodes powered by an energy generator comprising multiple data, information and voice gathering, receiving and emitting devices as well as mechanical, optical and propulsion devices..
09/19/13
20130246088
Algorithm for predicting and mitigating adverse events
A patient support apparatus includes a control system operable to gather physiological information about a patient supported on the patient support apparatus. The information may be gathered from sensors, a user interface, or a hospital information system.
09/19/13
20130246083
Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
This disclosure relates to methods of authorizing distribution of complement-inhibiting drugs to patients who have a complement-associated disorder in a manner to ensure that the patients are aware of the possible dangers of discontinuing treatment with the drugs. A database is prepared comprising patient information including experiencing adverse clinical events after discontinuing the drug treatment.
09/19/13
20130244892
Risk factors and prediction of adverse events
Biomarkers, methods, systems, and related teachings are disclosed for diagnosing the risk of an adverse event in a human, where the adverse event can be unstable angina, ischemic stroke, non-ischemic stroke, all-cause stroke, heart failure, all-cause death, and being a candidate for coronary revascularization surgery.. .
08/29/13
20130225639
Altering pharmacokinetics of pirfenidone therapy
The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) therapy.. .
08/29/13
20130220871
Method of providing pirfenidone therapy to a patient
The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone.
08/01/13
20130196954
Method of treating acne
An improved method for treating acne is described. The method involves 16-week, once daily, oral administration of about 40 mg doxycycline in a pharmaceutical composition containing about 30 mg doxycycline in an immediate release portion and about 10 mg doxycycline in a delayed release portion.
07/11/13
20130179375
Signal detection algorithms to identify drug effects and drug interactions
An algorithm according to an embodiment of the present invention provides for latent signal detection of adverse events. Embodiments infer the presence of adverse drug events from large observational databases housed by the fda, who, and other governmental organizations.
07/11/13
20130179187
Systems and methods for de-risking patient treatment
The present disclosure describes systems and methods for de-risking patient treatment by identifying medications or combinations of medications to be contraindicated for a specific indication. An analyzer executed by a processor of a computing device from a user may receive an identification of an indication (e.g.
07/11/13
20130179181
Systems and methods for personalized de-risking based on patient genome data
The present disclosure describes systems and methods for using patient-specific genomic information to optimize or de-risk therapy for the patient. A user may identify a medication for consideration for prescription to a patient, and a genetic variant of the patient affecting a first protein.
07/11/13
20130179138
Systems and methods for using adverse event data to predict potential side effects
The present disclosure describes systems and methods for predicting a likely side effect profile for even new, untested medications. A predicted side effect profile may be generated based on intersections of side effect profiles of other medications that affect the same or related molecular entities, such as the nearby target proteins, involve the same pathways, or are otherwise similarly related.
07/11/13
20130179091
Systems and methods for identifying unknown drug targets via adverse event data
The present disclosure is directed to systems and methods for identifying unknown drug targets via adverse event data. An analyzer receives an identification of a first drug having one or more unknown target proteins and identifies a second drug related to the first drug.
07/04/13
20130172281
Compositions for treating heartworm infestation
The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against dirofilaria parasites, without the risks for secondary adverse events of conventional formulations.
06/06/13
20130144652
Systems and methods for assessing medical record complexity and risk of adverse events
Methods and apparatus for analyzing an electronic medical record (emr) are provided. The method includes assigning to at least one document in the emr, a first value, wherein the assigning is based, at least in part, on a number of characters and/or a number of digits included in each document of the at least one document, determining a second value, wherein the second value is determined based, at least in part, on the first values, determining whether the second value is above a threshold value, and outputting an indication that the second value is above the threshold value.
05/23/13
20130133091
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
05/23/13
20130132125
System and method for providing insurance
A system and method for providing post-operative insurance in a surgical procedure involving implantation of a foreign material into a human body includes underwriting an insurance policy to cover an adverse event resulting from the procedure that may occur from a completion date of the procedure up to at least one year from the completion date of the procedure from a completion date of the procedure. The method further includes determining eligibility for enrollment of a patient undergoing the procedure and providing the insurance policy to the patient if the patient is eligible to enroll.
05/16/13
20130122530
Prediction and recognition of acute kidney injury after surgery
Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury aki as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (l-fabp) in a sample, such as a urine-sample of a subject; comparing the amounts of the l-fabp with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject..
04/11/13
20130089603
Compositions and methods for treating obesity and obesity-related conditions
A method to effectively treat the adverse events of ingested lipase inhibitor such as orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric-coated activated charcoal to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.. .
04/11/13
20130086933
Controller for a medical products storage system
A medical product storage device includes a controller that operates an access control system to limit access to a storage space of the medical product storage device. The controller monitors a temperature in the storage space and other operating parameters of the medical product storage device.
03/07/13
20130060235
Pharmaceutical compositions and methods of use
The present invention provides a pharmaceutical composition comprising a chemical compound or a herb extract or the combination having at least one of the activities of antiviral, antibacterial, antifungal, anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, for the treatment and prevention of a disease of a mammal. The pharmaceutical composition is to be delivered into the hard-to-reach sinuses of a mammal by using a unique sinonasal delivery device.
03/07/13
20130060163
Sinonasal specimen collection kit and use
The present invention additionally provides a kit for collecting the sinonasal specimen to analyze which pathogenic microbes cause a disease in a mammal, how to test the drug sensitivity against the infectious microbes in sinonasal cavities, and to help the selection of a pharmaceutical composition to selectively treat a disease of a mammal. The present invention also provides a pharmaceutical composition comprising a chemical compound or a herb extract or the combination having at least one of the activities of antiviral, antibacterial, antifungal, anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, for the treatment and prevention of a disease of a mammal.
01/03/13
20130005764
Quinine dosage forms and methods of use thereof
Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed are methods of using quinine and informing a user of information, including potential adverse effects, the effect of food on quinine's pharmacokinetics, effect of dosing various strengths of quinine, effect of maximum plasma concentrations of quinine in a patient as it relates to adverse events, effects of deviating from the prescribed dosage, etc..


Popular terms: [SEARCH]

Adverse Event topics: Adverse Event, Clindamycin, User Interface, Pirfenidone, Adverse Effect, Doxycycline, Glucocorticoid, Psychiatric, Amelioration, Neurological, Prophylaxis, Gastric Balloon, Food And Drug Administration, Computer Readable, Electronic Health Record

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Adverse Event for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Adverse Event with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



4.4688

2888

5 - 0 - 59